- Home
- RWAY vs AMRN Comparison
RWAY vs AMRN Comparison
Compare RWAY & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RWAY | AMRN |
|---|---|---|
| Founded | 2015 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 321.2M | 339.8M |
| IPO Year | N/A | 1998 |
Fundamental Metrics
Financial Performance| Metric | RWAY | AMRN |
|---|---|---|
| Price | $6.85 | $14.61 |
| Analyst Decision | Buy | Strong Sell |
| Analyst Count | 7 | 1 |
| Target Price | $9.86 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 470.2K | 79.9K |
| Earning Date | 03-12-2026 | 05-06-2026 |
| Dividend Yield | ★ 19.91% | N/A |
| EPS Growth | N/A | ★ 55.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $181,104,000.00 |
| Revenue This Year | $6.75 | N/A |
| Revenue Next Year | $5.12 | $1.26 |
| P/E Ratio | $5.70 | ★ N/A |
| Revenue Growth | N/A | ★ 39.22 |
| 52 Week Low | $6.61 | $0.39 |
| 52 Week High | $11.41 | $20.90 |
Technical Indicators
Market Signals| Indicator | RWAY | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 27.79 | 43.84 |
| Support Level | N/A | $13.63 |
| Resistance Level | $9.53 | $14.55 |
| Average True Range (ATR) | 0.22 | 0.80 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 15.61 | 22.16 |
Price Performance
Historical ComparisonAbout RWAY Runway Growth Finance Corp.
Runway Growth Finance Corp is a specialty finance company focused on providing senior secured loans to high-growth-potential companies in technology, life sciences, healthcare information and services, business services, select consumer services and products, and other high-growth industries. The company has Investments in the United States, Germany, and UK, Canada, Netherlands, with the majority of its portfolio invested in the United States.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.